Molecular analysis of a novel PTEN binding protein SCYL2 function
| Project/Area Number |
15K08310
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathological medical chemistry
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | がん / PTEN / リン酸化 / シグナル伝達 / 癌 |
|---|
| Outline of Final Research Achievements |
We reported that inactivation of PTEN by the phosphorylation plays an important role in the development of Adult T-cell leukemia (ATL) and cancers through the aberrant activation of PI3K/AKT signaling pathway. We identified SCYL2 (SCY1-like protein 2) as a novel PTEN binding protein. Although SCYL2 associated with Clathrin to regulate endocytosis and signaling pathways, it is still unclear how SCYL2 regulates phosphorylation statue of PTEN. SCYL2 was highly expressed in ATL cells, and localized in cytoplasm with PTEN. Knockdown of SCYL2 expression suppressed cell proliferation and tumorigenesis through the dephosphorylation of AKT and PTEN. We suggested that PTEN at the Ser380, Thr382 and Thr383 cluster with the C-terminal tail was directly phosphorylated by SCYL2. Furthermore, the inhibition of Clathrin function decreased the phosphorylated PTEN and cell proliferation in ATL. SCYL2 inhibition may become promising novel targets for cancer diagnosis and therapy in many type of cancer.
|
Report
(4 results)
Research Products
(19 results)
-
[Journal Article] Development of Oral Squamous Cell Carcinoma (OSCC) with Enhanced Metastatic Potential Through Loss of NDRG2 Expression.2017
Author(s)
Tamura, T., Ichikawa, T., Nakahata, S., Kondo, Y., Tagawa, Y., Yamamoto, K., Nagai, K., Baba, T., Yamaguchi, R., Futakuchi, M., Yamashita, Y., and Morishita, K.
-
Journal Title
Cancer Res
Volume: 印刷中
Issue: 9
Pages: 2363-2374
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
[Journal Article] Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.2017
Author(s)
Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, Kubuki Y, Kurosawa G, Zhang L, Sudo Y, Shimoda K, Morishita K.
-
Journal Title
Biochem Biophys Res Commun.
Volume: 485
Issue: 1
Pages: 144-151
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
